Early trials suggest that the compound – a dual agonist of GLP-1 and GIP receptors – presents a significant breakthrough in weight reduction efforts . Unlike existing medications , the peptide shows to modify hunger and metabolic utilization through distinct pathways . Despite more analysis is required , the results spark excitement for a inno